carpal tunnel syndrome. Mononeuropathy in diseases classified elsewhere
Conditions
Interventions
Intervention 1: Intervention group: 2cc ozone 20µg / L, around the median nerve with Medial approach as in-plane under ultrasound guidance. Intervention 2: Control group (corticosteroid therapy ): 1cc
Sponsors
Tabriz University of Medical Sciences
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Cavernous carpal tunnel syndrome confirmed by Electrodiogenesis (EDX) criteria Severe moderate carpal tunnel syndrome that is proven by EDX criteria The presence of paresthesia or numbness in the median nerve pathway Unwillingness of the patient to undergo surgery SNAP amplitude decrease NCV across wrist smaller than 40 m/sec Peak SNAP latency larger than 3.6 msec CMAP latency larger than 4.2 msec
Exclusion criteria
Exclusion criteria: The presence of severe atrophic symptoms or severe CTS in EMG-NCV. Contraindications for corticosteroid injection such as corticosteroid allergy and injection site infections CTS treatment with surgery or corticosteroid injection in the last 6 months Traumatic or neoplastic origin of symptoms Not having satisfaction for injection CMAP amplitude absence (CMAP) or the presence of symptoms of fib / psw in tense muscles Signs of Cervical Activated Radiculopathy in Nidal Electromigraphy or Extruded Cervical Discs in MRI
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain score based on Visual Analogue Scale. Timepoint: Before injection, 2 weeks and 8 weeks after injection. Method of measurement: Visual Analogue Scale.;The functional limitations and symptoms severity scales on Boston Questionnaire. Timepoint: Before injection, 2 weeks and 8 weeks after injection. Method of measurement: Boston Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical Global Impression. Timepoint: Before injection, 1 weeks and 8 weeks after injection. Method of measurement: Clinical Global Impression Questionnaire.;Patient Global Impression of Improvement. Timepoint: Before injection, 1 weeks and 8 weeks after injection. Method of measurement: Patient Global Impression of Improvement Questionnaire.;Electromyographic findings. Timepoint: Before injection, 1 weeks and 8 weeks after injection. Method of measurement: Nerve strip.;Median nerve cross section. Timepoint: Before injection, 1 weeks and 8 weeks after injection. Method of measurement: sonography.;Channel depth. Timepoint: Before injection, 1 weeks and 8 weeks after injection. Method of measurement: sonography.;Flexor Retinaculum Thickness. Timepoint: Before injection, 1 weeks and 8 weeks after injection. Method of measurement: sonography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBina Efrekharsaadat
Physical Medicine & Rehabilitation Research Center
Outcome results
None listed